BALTIMORE, April 3, 2008 Lentigen Corporation todayannounced an exclusive licensing agreement with Cambridge Enterprise, theorganization responsible for licensing technologies from the University ofCambridge (U.K.), for a fundamental patent in the area of lentiviral vectortechnology. The technology was developed in the laboratory of Professor AndrewLever at the University of Cambridge.
"The patent broadly claims fundamental compositions of HIV-basedlentiviral vectors that are currently widely used in research and clinicalstudies," said Boro Dropulic, Ph.D., founder, president and chief scientificofficer of Lentigen. He added "we are delighted to be working with ProfessorLever in obtaining this patent license, and developing its application inbiomedicine."
Following the acquisition of the Cell Genesys' lentiviral patent portfoliolate last year by GBP Capital, the majority shareholder in Lentigen, thislicense further consolidates Lentigen's intellectual property position.
"Licensing this fundamental technology patent from the University ofCambridge extends our strong intellectual property position and is consistentwith our goal of becoming a leader in lentiviral-vector based biomedicine. Itfurther enables Lentigen to pursue development and commercialization ofbiomedical products and services, to the benefit of patients, healthcareproviders and the research community," said Tim Ravenscroft, chief executiveofficer of Lentigen.
"Lentigen are the ideal partner for this piece of fundamental lentiviralvector technology. We are pleased to be working with a team committed todeveloping the technology for patient benefit," added Dr Andrew Walsh,technology manager for Cambridge Enterprise, University of Cambridge.
About Lentiviral Vectors
Lentiviral vectors (LV) are the most efficient vehicles for stabledelivery of genes or gene silencing sequences (e.g. RNAi) into cells. Genedelivery is accomplished by the binding and fusion of the LV pseudotypedenvelope protein to the target cell membrane. The LV genomic RNA comprisingthe gene or gene silencing sequence is then converted to DNA and permanentlyintegrates into the cell's genome with extraordinary high efficiency. The geneor gene silencing sequence is then expressed in the cells, resulting in cellsthat are permanently genetically engineered with the desired effect.
About Lentigen Corporation
Lentigen Corporation is a privately owned biotechnology company focused onthe development of lentiviral vector technology for a wide range oftherapeutic, vaccine, and research applications in biotechnology and medicine.Lentiviral vectors are the most efficient vehicles for the delivery of genesor gene silencing sequences stably into cells. Lentigen is a highlycollaborative company, co-developing lentiviral vector-based products across abroad spectrum of bench to clinical applications. Partnerships include TheNational Institutes of Health, The University of Pennsylvania, ThermoFisherScientific and The U.S. Army. For further information, visithttp://www.lentigen.com/
Cambridge Enterprise Limited, University of Cambridge
Cambridge Enterprise Limited provides knowledge and technologycommercialisation services to University staff and students. Services includeintellectual property management, bespoke marketing, negotiation of technologylicences and consultancy services. Additionally, Cambridge Enterpriseprovides specialist surgeries for new companies, one-to-one mentoring byexperienced business people, and provides access to seed and venture capitalthrough the Cambridge Enterprise Seed Funds and Cambridge Enterprise VenturePartners.
On 1st December 2007 Cambridge Enterprise marked its first birthday as alimited company. During this first year the performance was solid in that 60licences and 95 consultancy contracts were closed and the company ass